Lunai Bioworks Inc. develops AI-enabled life sciences platforms for drug discovery, precision therapeutics and chemical defense applications. Company news centers on the Augusta platform, BioSymetrics' phenotypic screening and machine-learning capabilities, and programs tied to central nervous system diseases, oncology and biodefense.
Recurring updates include intellectual property additions, patent issuances, commercial collaborations, defense-focused chemical threat assessment work, and capital transactions used to support platform expansion. Recent company developments also cover CNS delivery technologies, neurotherapeutic patent assets, patient-stratification methods, and the integration of clinical, genomic and phenotypic data into drug discovery workflows.
Lunai Bioworks (NASDAQ: LNAI) completed a $20.0 million Series B preferred issuance on May 1, 2026 to acquire CNS delivery and neurotherapeutic IP, adding a BBB‑crossing prodrug system and a nose‑to‑brain (N2B) delivery pathway.
The assets will be integrated into a wholly owned subsidiary to support Alzheimer's and other neurological programs, 505(b)(2) pathways, combination therapies, biodefense countermeasures, and potential partnerships. The company believes stockholders' equity exceeds the $2.5 million Nasdaq minimum and awaits the Panel's formal determination.
Lunai Bioworks (NASDAQ: LNAI) subsidiary BioSymetrics signed a non-binding LOI with Geneial to convert patient-led rare neurological datasets into trial-ready cohorts and pursue commercial pharma partnerships. Initial programs will integrate longitudinal registry data to identify patient subgroups and enable cohort activation for translational and clinical development.
Lunai Bioworks (NASDAQ: LNAI) announced a revenue-generating, multi-year defense collaboration through its subsidiary BioSymetrics to deploy an AI-enabled platform for chemical threat assessment.
The program integrates in vivo zebrafish phenotypic screening with AI-driven mechanism-of-action prediction, targets neuroactive and neurotoxic compounds, and can screen hundreds to thousands of compounds per week while additional engagements are under discussion.
Lunai Bioworks (NASDAQ: LNAI) executed a binding $20.0 million strategic transaction to acquire a blood-brain barrier delivery platform and CNS Alzheimer's drug assets from Clemann Group, structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share with a 19.9% beneficial ownership limitation.
The deal contains no variable pricing or resets and is described as NASDAQ compliant. The platform enables compounds to cross the BBB, activate selectively in the brain, and targets pathways tied to acetylcholinesterase modulation, strengthening Lunai's CNS Alzheimer’s pipeline and broader CNS development capabilities.
Lunai Bioworks (NASDAQ: LNAI) launched the Pathfinder Consortium on March 19, 2026, a national academic–industry alliance to accelerate chemical countermeasure discovery and federal stockpiling.
The consortium aims to compress countermeasure development to ~36 months and target U.S. procurement programs sized between $400M and $1.2B per program, leveraging BioSymetrics' AI phenotypic platform and multi‑partner execution.
Lunai Bioworks (NASDAQ: LNAI) announced issuance of U.S. Patent No. 12,369,861 on Feb 19, 2026 for "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions."
The patent covers Lunai's foundational multimodal data standardization and bias-removal layer used before predictive AI modeling, intended to improve biomarker discovery, disease subtyping, and gene network mapping across CNS, oncology, and biodefense programs.
Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC Business Minute on Feb 13, 2026. CEO David Weinstein described the company’s proprietary AI platform for accelerating therapeutic discovery in CNS disorders and strengthening biodefense preparedness.
The platform integrates multimodal biological datasets, advanced machine learning, and in vivo validation to identify targets, optimize candidates, and compress development timelines. The company said it is advancing discussions with pharmaceutical firms and government agencies about its biotech and biodefense capabilities.
Lunai Bioworks (NASDAQ:LNAI) says its Augusta AI platform is now commercial after 12 months of development and is in active negotiations with pharmaceutical and drug‑discovery partners. The company highlights three revenue engines: AI drug discovery (CNS and new oncology pilot), AI biodefense programs targeting government contracts, and an allogeneic dendritic cell immunotherapy with published preclinical tumor regressions and an LOI for licensing.
The release emphasizes faster target validation via high‑throughput in vivo testing, near‑term pilots that can expand to commercial relationships, and ongoing efforts to finalize biodefense funding and a pharma royalty partnership.
Lunai Bioworks (NASDAQ: LNAI) launched an AI oncology pilot on Feb 9, 2026 to analyze randomized Phase 2 metastatic colorectal cancer trial data with a clinical-stage partner. The pilot uses Lunai's Augusta AI platform to evaluate de-identified patient-level clinical, imaging, and longitudinal outcomes focusing on overall survival and disease progression.
The goal is to define biologically meaningful patient subgroups to inform FDA trial design, optimized inclusion criteria, endpoint strategy, and statistical powering, with potential expansion to multi-study commercial programs and other tumor types if data support it.
Lunai Bioworks (NASDAQ: LNAI) launched Sentinel, a transformer-based AI safeguard that embeds inside large language and scientific foundation models to screen and block generation of novel chemical threat agents in real time. Sentinel combines Lunai's chemical foundation model trained on ~550 million public chemical structures and fine-tuned with the company's proprietary in-vivo toxicology and phenotypic datasets to detect latent toxic signatures and mechanisms, including neurotoxic and cytotoxic patterns. The product is positioned as part of a three-program biodefense strategy alongside Pathfinder and Counteract and targets AI developers, government agencies, and life-science platforms seeking integrated molecular-level biosecurity.